Get started
Author

Carmen Blasco

VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects
2021 · Miriam Bazan-Peregrino, Rocio Garcia-Carbonero, et al. · Journal for ImmunoTherapy of Cancer · 113
PDF
Critical Role of Mitochondrial Glutathione in the Survival of Hepatocytes during Hypoxia
2004 · Josep M. Lluis, Albert Morales, et al. · Journal of Biological Chemistry · 107
PDF
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors
2022 · Rocio Garcia-Carbonero, Miriam Bazan-Peregrino, et al. · Journal for ImmunoTherapy of Cancer · 104
PDF
Differential role of ethanol and acetaldehyde in the induction of oxidative stress in HEP G2 cells: Effect on transcription factors AP-1 and NF-κB
1999 · Juan Román, Anna Colell, et al. · Hepatology · 86
Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study
2015 · Miguel J. Gil-Gil, M. Bellet, et al. · Breast Cancer Research and Treatment · 55
Systemic administration of the hyaluronidase-expressing oncolytic adenovirus VCN-01 in patients with advanced or metastatic pancreatic cancer: First-in-human clinical trial
2019 · R. Garcia-Carbonero, M. Gil Martín, et al. · Annals of Oncology · 13
Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al. · Clinical Cancer Research · 4
2216MO VIRAGE trial: Randomized phase IIb, open-label, study of nab-paclitaxel and gemcitabine with/without intravenous VCN-01 in patients with metastatic pancreatic cancer (mPDAC)
2025 · R. Garcia-Carbonero, R.A. Pazo Cid, et al. · Annals of Oncology · 4
VIRAGE: A phase IIb, open-label, randomized study of nab-paclitaxel and gemcitabine plus/minus VCN-01 in patients with metastatic pancreatic cancer.
2024 · Rocio Garcia-Carbonero, Roberto Pazo Cid, et al. · Journal of Clinical Oncology · 3
Proof of concept clinical study by US-guided intratumor injection of VCN-01, an oncolytic adenovirus expressing hyaluronidase in patients with pancreatic cancer
2019 · M. Hidalgo, M. Bazan-Peregrino, et al. · Annals of Oncology · 2
128TiP VCN-01 plus durvalumab in subjects with recurrent/metastatic head & neck squamous cell carcinoma (R/M HNSCC): Phase I clinical trial
2019 · M. Jove, I. Braña, et al. · Annals of Oncology · 1
Cellular Distribution of Reduced Glutathione During Cell Cycle in 3T3 Fibroblasts
2005 · José Viña, Federico V. Pallardó, et al. · Proceedings of The Physiological Society · 1
Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial
2026 · Rocio Garcia-Carbonero, Roberto Pazo Cid, et al. · Nature Medicine
Table S5 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Figure S6 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Figure S3 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Figure S11 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Table S6 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Figure S10 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Figure S7 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Figure S4 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Table S8 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Table S9 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Figure S9 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Table S1 from Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy
2026 · Maria Jove, Irene Braña, et al.
Works count: 39
Citation count: 493
H-index: 6
I10-index: 6
Year
Topic
Type